Buying Mounjaro and Wegovy in Australia: TGA rules and import

Start with the ARTG and Australian product information

Look up the exact medicine and presentation on the Australian Register of Therapeutic Goods (ARTG), then read the Australian product information. Ask the pharmacist whether your product is registered locally or supplied through an exceptional pathway. A UK or US label does not answer that question. Check tablets and injections separately, especially when one international brand comes in more than one form.

Mounjaro is approved in Australia for diabetes and weight management

The TGA has approved Mounjaro for type 2 diabetes and chronic weight management. The weight-management extension was registered on 10 September 2024. Adults qualify with a BMI of at least 30, or at least 27 with a weight-related condition, alongside a reduced-calorie diet and more physical activity. These Australian criteria give you a firmer starting point than a brand's indication from another country.

A later TGA safety communication also lists obstructive sleep apnoea in adults with obesity. Having one of these conditions does not mean you should get the medicine. Ask your clinician which current Australian indication and product information apply, then ask about funding as its own question. Registration does not guarantee a Pharmaceutical Benefits Scheme subsidy, whatever a commercial programme suggests.

Wegovy injection is approved for adults and some adolescents

The TGA registration entry for Wegovy is dated 1 September 2022. It covers chronic weight management in adults with a BMI of at least 30, or at least 27 with a weight-related condition, alongside diet and activity measures. A separate TGA decision added qualifying adolescents aged 12 and over. Each approval covers a defined patient group. None of them is a general recommendation for anyone who wants to lose weight.

Later TGA entries add cardiovascular risk reduction in certain adults with established cardiovascular disease and overweight or obesity. They also add treatment of non-cirrhotic MASH with moderate-to-advanced liver fibrosis. Each indication has its own conditions. When you buy, ask which current Australian label supports your prescription. The list of benefits in an overseas advert does not matter. Ask the pharmacist for the Australian Consumer Medicine Information for the exact presentation you receive.

Wegovy tablets need their own Australian approval

Wegovy injection approvals appear in TGA records. A Wegovy tablet approval does not appear in the TGA records cited below. Rybelsus is a separate oral semaglutide product, and its Australian history does not prove an oral Wegovy weight-management approval. If an Australian service offers a Wegovy pill, ask for the exact ARTG entry and product information, or a clear account of the lawful exceptional-access pathway it relies on.

Oral semaglutide studies, an overseas launch or a risk-management document mentioning tablets do not prove the finished product is registered here. Both the formulation and the indication must match. Never work out an oral dose from your weekly injection dose. A pharmacy should not swap one semaglutide product for another without your prescriber's direction.

Orforglipron (Foundayo) is under TGA evaluation

A TGA evaluation record shows an orforglipron calcium application from Eli Lilly Australia, accepted in January 2026. The proposed indication uses the name NEXVOUND and covers adult weight management and type 2 diabetes. An application record is not an approval. The record is dated, so the application may have moved on since. The record also does not show Foundayo as an Australian brand name. Check the final name, registration and label in the current ARTG and the latest decision records.

Check the current record before you act, because evaluations move on. A missing registration does not mean possession is banned outright. Ordinary local supply of a registered product works differently from conditional personal import or exceptional access. A seller should tell you which pathway it is using. An overseas approval does not give Australian permission.

What to ask a provider before you buy

For an established Australian injection, start with a local clinical assessment and a pharmacy quote for the right presentation. For a newer oral product, settle its regulatory status before you look at any discount or subscription. Ask the provider for the ARTG identifier, product name and Australian patient information in writing. If the provider offers an unapproved medicine, ask why a registered option does not suit you and which authorisation or exemption covers the supply.

Keep those details with your prescription and invoice. Another clinician or pharmacist will then know what you received if you move, travel or have a problem. A product's research stage or its marketing overseas does not replace this record. If stock runs out, get a clinician-led alternative or a plan for the gap. Do not switch between brands, tablets and injections on your own.

Personal Importation Scheme conditions

The TGA scheme usually limits a single import to three months of treatment and sets other conditions. For prescription-only medicines you must hold a valid Australian prescription or written authority at the time of import, and the medicine must be for permitted personal use. The scheme gives no permission to sell imported medicines or to skip a clinical assessment. Read its current packaging, quantity and product limits before you order.

Travellers follow different rules from posted orders

The traveller exemption covers medicines you carry with you. A posted order falls under the import rules. Do not use a travel allowance to justify an unrelated mail order. For a long visit, ask how later supplies and local prescribing will work. Keep the original packaging and proof of your prescription. If you inject, ask about the device and needles as well.

Check PBS funding and delivery separately

An ARTG listing does not mean the Pharmaceutical Benefits Scheme subsidises your exact indication. Ask your clinician and pharmacist how you will pay, and get the full private price if needed. Long distances and hot weather can delay or warm deliveries, so ask how the pharmacy deals with either. If you are unsure how a parcel was stored, ask the pharmacist before use. Appearance alone does not tell you whether the medicine is still good.

Product status in Australia

Mounjaro and Wegovy injection have confirmed Australian approvals in the sources below. Oral Wegovy approval does not appear in them, and the orforglipron record describes an application under evaluation. Check the current ARTG entry and product information. Registration, clinical eligibility, public subsidy, stock and import permission each need their own check.

• Ask an Australian clinician which product suits you and whether your treatment history is enough for an assessment.
• Get the full cost, including consultations, dispensing and delivery, before you commit to ongoing treatment.
• Keep the packaging, the prescription and the dispensing record. If a parcel arrives damaged or its storage is uncertain, ask the pharmacist before you use the medicine.